Soyuz rocket departs for the international space station in historic final U.S.-Russian flight

BAIKONUR COSMODROME, Kazakhstan — Since the launch of Sputnik and Yury Gagarin from the desert steppe of Kazakhstan over 60 years ago, the history of spaceflight has been measured in milestones.

The first satellite, the first human in space, the first to the Moon. But the launch of Soyuz MS-17 on Wednesday was a different kind of milestone: the end of an era.

At 8.45 a.m. local time, a Soyuz rocket blasted off from Baikonur Cosmodrome, Russia’s sprawling and remote space launch facility in Kazakhstan, to the International Space Station.

It was the last time NASA paid for an American astronaut to fly with the Russian Space Agency, Roscosmos, on such a flight. Next year, for the first time since the start of the ISS program 20 years ago, Russia will fly all-Russian crews on Soyuz.

NASA astronaut Kate Rubins and Russian cosmonauts Sergey Ryzhikov and Sergey Kud-Sverchkov board the
Read More
Read More

Tech Moves: Expedia and F5 Networks add board members; Madrona principal departs; and more

Beverly Anderson. (Expedia Group Photo)

— Expedia Group appointed Equifax President of Global Consumer Solutions Beverly Anderson as its newest board member.

Prior to Equifax, Anderson was executive vice president of cards and retails services at Wells Fargo. She also held executive roles at American Express and Fleet Credit Card Services.

Maria Karaivanova. (Madrona Photo)

— Maria Karaivanova departed Madrona Venture Group, where she was a principal, to join Allen Institute for Artificial Intelligence spinout WhyLabs as a co-founder and COO.

The Seattle startup came out of stealth mode last week and announced a $4 million investment round, which included participation from Madrona. Karaivanova helped lead Madrona’s investment.

— Seattle biotech startup Silverback Therapeutics promoted Valerie Odegard to president and Naomi Hunder to chief medical officer. 

Odegard joined the company in 2016 as chief scientific officer. She was previously vice president of research at Juno Therapeutics, which was acquired by

Read More
Read More